Corneal Epithelium Repair and Therapy Using Autologous Limbal Stem Cell Transplantation
Corneal Disease, Pterygium, Myopia
About this trial
This is an interventional treatment trial for Corneal Disease focused on measuring Corneal disorders, Chemical injury, Pterygium, Refractive error, Myopia, Hyperopia, Cornea, Monocular, Transparent, Transplantation, Visual function
Eligibility Criteria
Inclusion Criteria:
- Monocular corneal chemical injury or pterygium, or refractive error greater than +/- 2D
- Informed consent signed by patient or legal guardian
Exclusion Criteria:
- Patients with a history of corneal perforation or surgery
- Patients with other eye diseases
- Patients with a history of severe cardiovascular, liver, kidney, endocrine, and hematopoietic disease, diabetes, or immune deficiency disorders
- Pregnant or lactating women
- Patients who are participating in other clinical trials
- Patients with a history of mental illness who are unable to give informed consent or follow up according to the study protocol.
Sites / Locations
- Zhongshan Ophthalmic Center, Sun Yat-sen UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Active Comparator
Experimental
Active Comparator
LSCs and amniotic membrane (Modified Technique)
Amniotic membrane only (Traditional Technique)
PRK, LSCs, and amniotic membrane (Modified Technique)
PRK only (Traditional Technique)
Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following removal of scar tissue due to chemical injury or pterygium. The contact lens will then be covered with amniotic membrane to secure it in place. The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched.
Amniotic membrane alone will be used to cover the corneal surface, after removal of scar tissue from a chemical injury or pterygium.
Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following photo-refractive keratectomy (PRK). The contact lens will then be covered with amniotic membrane to secure it in place. The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched.
PRK alone will be performed.